Match Point Partners, a leading digital health advisory firm, advised Qcentive LLC on its Q3 2019 merger with Apervita, Inc., a leading cloud collaboration platform designed exclusively for the healthcare industry. Qcentive—a leader in value-based contract and alternative payment administration—was originally incubated and launched by Blue Cross Blue Shield of Massachusetts (BCBSMA) and its venture investment subsidiary, Zaffre Investments. The combined Apervita-Qcentive solution integrates clinical and financial insights and empowers payers and providers to create and manage value-based relationships that drive greater efficiency and quality of care. Previously, Match Point had advised Apervita on its 2017 financing round.
Commenting on the transaction and Match Point’s role, Patrick Gilligan, executive vice president of Sales, Marketing and Product for BCBSMA and chief executive of its venture investment subsidiary, Zaffre Investments, said, “We incubated Qcentive with the intent of sharing its innovations with the broader market. The combination of Apervita and Qcentive makes this vision a reality. Match Point hit a home run in making this match happen.”
Qcentive Co-founder and CEO Christopher Pilkington agreed, commenting, “Value-based relationships are critical building blocks to transforming the archaic way the U.S. buys and sells healthcare. The Apervita-Qcentive combination is the first healthcare industry platform with the ingredients to make that happen at scale. Kudos to Match Point for bringing us together.”
The Qcentive-Apervita deal followed the successful sale earlier this year of DoseMe® to Tabula Rasa HealthCare® (TRHC) (NASDAQ: TRHC), a healthcare technology company advancing the field of medication safety. DoseMe’s unique AI-driven dosing solutions support physicians and pharmacists to accurately dose patient’s high-risk parenteral medications based on their individual needs, resulting in significant improvements to patient safety and outcomes.
“By uniting DoseMe and TRHC, we are able to more effectively support healthcare providers to enhance and accelerate medication safety solutions,” states Charles Cornish, CEO of DoseMe. “Together we believe we can power the shift to precision prescribing, tailoring medication to meet individual needs. This will have a profound impact on safety, quality and costs, including medication-related adverse drug events. Match Point was key in connecting our two innovative organizations.”
Brad Burkett, managing partner of Match Point commented, “Match Point’s unique hands-on style—leveraging its partners’ decades of CXO experience in early-stage companies and transactions—is extremely well suited to the fast-emerging fields of AI, analytics and platform-as-a-service. Early stage companies in these sectors have important solutions that will dramatically transform health care cost and quality. We are gratified to be able to assist talented ventures like Qcentive and DoseMe to grow and achieve their vision.”
Match Point was founded by entrepreneurs for entrepreneurs. Since its founding in 2009, we have assisted over 100 emerging healthcare firms to achieve outstanding success and exceed their vision.See the latest posts on our homepage